Opinion|Videos|October 17, 2024
Advocacy Groups and Integration of Wellness Strategies into Treatment for Parkinson’s Disease
Author(s)Stuart H. Isaacson, MD, FAAN
Key Takeaways
- Integrating nutrition and exercise into PD treatment plans can improve patient outcomes and quality of life.
- Encouraging patient adherence to wellness habits and pharmacological therapy is essential for effective PD management.
Dr. Isaacson discusses how physicians can effectively integrate wellness strategies such as nutrition and exercise into treatment plans for Parkinson's disease (PD), encourage patient adherence to these habits alongside pharmacological therapy, and leverage advocacy groups as vital resources for both patients and health care professionals (HCPs) in navigating wellness and care management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How should physicians integrate wellness strategies, such as nutrition and exercise, into the treatment plans for patients with PD?
- What should HCPs do to encourage patients to adopt and maintain wellness habits and comply with pharmacological therapy for PD?
- What is the role of advocacy groups for patients in navigating PD, especially in adopting and encouraging wellness habits?
- How can HCPs leverage these resources in their practices?
- Are there any advocacy groups that are focused on HCPs in PD?
Advertisement
Related to this article
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease biomarkers!
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in glioblastoma beyond extent of resection and sex.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
A published protocol outlines the randomized, open-label EPOCH trial testing whether cilostazol accelerates hematoma resorption and improves recovery after intracerebral hemorrhage.
Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes]
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
4
NeurologyLive® Brain Games: September 20, 2026
5